Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAVENCLAD vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cladribine is a prodrug that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to lymphocyte depletion. It selectively targets and reduces circulating T and B lymphocytes, thereby modulating the immune response in multiple sclerosis.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
FDA: Treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive disease.
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
3.5 mg/kg body weight administered orally as two treatment courses of 1.75 mg/kg each over two consecutive weeks (cumulative dose 3.5 mg/kg per year). Each course is given as a 14-day period: 1.75 mg/kg in divided doses daily for 4 or 5 days, depending on patient preference (e.g., 10 mg tablets daily for that period).
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Terminal elimination half-life of cladribine is approximately 5.7 days (range 4-10 days) following oral administration. This long half-life supports once-daily high-dose short-course dosing and is due to slow release from lymphocytes. Clinical context: Allows sustained intracellular levels of active triphosphate in lymphocytes.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate metabolite. It is also phosphorylated by other nucleoside kinases. The elimination half-life is approximately 1 day. Renal excretion of unchanged drug accounts for about 18% of the dose.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Approximately 100% of cladribine dose is eliminated via renal excretion of unchanged drug and metabolites, with <5% recovered in feces. Renal clearance is about 2/3 of total clearance. Biliary elimination is negligible.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
20% bound to plasma proteins, primarily albumin. No significant binding to alpha1-acid glycoprotein.
Approximately 20–30% bound to plasma proteins.
Apparent volume of distribution is approximately 4.3 L/kg (range 1-9 L/kg). This large Vd indicates extensive extravascular distribution, including penetration into cells and tissues, particularly lymphocytes. Clinical meaning: High tissue distribution correlates with intracellular loading in target immune cells.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Oral bioavailability of cladribine from MAVENCLAD is approximately 40% (range 30-50%). It is converted to active triphosphate intracellularly, so prodrug absorption is similar. Food reduces absorption by ~20% but does not affect clinical effect.
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
Contraindicated in patients with estimated GFR <30 m L/min/1.73 m2 due to potential accumulation and increased risk of adverse reactions. No dose adjustment recommended for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m2).
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
Contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A).
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Not approved for use in pediatric patients less than 18 years of age. Safety and efficacy have not been established.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No specific dose adjustment recommended based on age alone. However, renal function should be assessed and dosing should be based on e GFR as in younger adults. Experience in patients over 60 years of age is limited.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
WARNING: MALIGNANCIES. Cladribine can increase the risk of malignancies (including cases of cancer-related deaths). Because of this risk, MAVENCLAD should be used in patients who have had an inadequate response to, or are unable to tolerate, other drugs indicated for the treatment of MS.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Risk of malignancies: including treatment-emergent malignancies (e.g., cancers of the lung, gastrointestinal tract, skin, breast, and others).,Hematologic toxicity: severe bone marrow suppression (thrombocytopenia, anemia, neutropenia); monitor CBC counts before and during treatment.,Infections: increased risk of serious infections, including opportunistic infections (e.g., tuberculosis, herpes zoster, progressive multifocal leukoencephalopathy); screen for latent infections before initiation.,Hepatic injury: cases of drug-induced liver injury; monitor liver enzymes.,Fetal risk: can cause fetal harm; advise females of reproductive potential to use effective contraception during and for 6 months after the last dose.,Vaccinations: avoid live vaccines during and after treatment.,Impaired renal function: use with caution; cladribine pharmacokinetics may be altered.
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
Current malignancy.,Patients with HIV infection.,Active chronic infections (e.g., tuberculosis, hepatitis).,Hypersensitivity to cladribine or any component of the formulation.,Women who are pregnant or breastfeeding.,Concomitant use with other immunosuppressive or myelosuppressive therapies (except corticosteroids for acute exacerbations).
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
No significant food interactions reported. Avoid grapefruit and grapefruit juice as they may alter drug metabolism.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
MAVENCLAD (cladribine) is contraindicated in pregnancy. Based on animal studies and its mechanism of action (cytotoxicity to rapidly dividing cells), there is an increased risk of fetal harm, including teratogenicity and embryolethality. In humans, no adequate controlled studies exist; therefore, use in all trimesters is contraindicated. Women of childbearing potential must use effective contraception during treatment and for at least 6 months after the last dose.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
It is unknown whether cladribine is excreted in human breast milk. However, due to the potential for serious adverse reactions in nursing infants and the drug's long half-life, breastfeeding is not recommended during treatment and for at least 10 days after the last dose. M/P ratio is not available.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
MAVENCLAD is contraindicated in pregnancy and should not be used. No dosing adjustments are applicable as the drug is not to be administered to pregnant women.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
Mavenclad (cladribine) is an oral purine antimetabolite approved for relapsing multiple sclerosis. It is given as two short courses per year for two years. Monitor for lymphopenia, infections, and malignancies. Contraindicated in patients with active infections or current malignancy. Do not use in patients with HIV or hepatitis B/C. Live vaccines contraindicated during and after treatment. Pregnancy category D; effective contraception required. Monitor liver enzymes and bilirubin. Consider PCP and VZV prophylaxis if lymphopenia severe. MRI monitoring for PML is recommended.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
Mavenclad is taken in two treatment courses per year, each consisting of 4 or 5 days of tablets, for 2 years.,You need regular blood tests to monitor your white blood cell count, liver function, and for infections.,Avoid live vaccines during treatment and for at least 1 year after the last dose.,Use effective contraception during treatment and for at least 6 months after the last dose.,Report any signs of infection (fever, chills, cough), unusual bleeding, or easy bruising immediately.,Do not take Mavenclad if you have an active infection, cancer, or HIV/hepatitis B or C.,Avoid grapefruit products during treatment.,Store tablets at room temperature away from moisture.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAVENCLAD vs CLADRIBINE, answered by our medical review team.
MAVENCLAD is a Antineoplastic Agent that works by Cladribine is a prodrug that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to lymphocyte depletion. It selectively targets and reduces circulating T and B lymphocytes, thereby modulating the immune response in multiple sclerosis.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAVENCLAD and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAVENCLAD is: 3.5 mg/kg body weight administered orally as two treatment courses of 1.75 mg/kg each over two consecutive weeks (cumulative dose 3.5 mg/kg per year). Each course is given as a 14-day period: 1.75 mg/kg in divided doses daily for 4 or 5 days, depending on patient preference (e.g., 10 mg tablets daily for that period).. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAVENCLAD and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAVENCLAD is classified as Category C. MAVENCLAD (cladribine) is contraindicated in pregnancy. Based on animal studies and its mechanism of action (cytotoxicity to rapidly dividing cells), there is an increased risk of . CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.